人乳头瘤病毒疫苗按剂次数的效果:国家免疫规划数据的系统综述
本文系统综述了国家免疫规划背景下人乳头瘤病毒(HPV)疫苗不同剂次的效果。共纳入14篇文献,多数研究显示三剂次效果最高,部分研究未发现两剂次与三剂次有统计学显著差异,近半数研究显示一剂次有一定效果;多种偏倚可能使两剂次和一剂次的效果被低估。
要点
- 多数上市后研究报告三剂次HPV疫苗效果最高。
- 部分研究未发现两剂次与三剂次效果有统计学显著差异。
- 近半数研究显示一剂次HPV疫苗有一定效果。
核心结论
- 多数上市后研究报告三剂次效果最高,部分研究未发现两剂次与三剂次有统计学显著差异,近半数研究显示一剂次有一定效果。
研究设计与样本
- 系统文献综述,检索到3787篇文章,评估26篇全文,最终纳入14篇。
- 所有研究均在推荐三剂次程序的背景下开展,涉及二价HPV疫苗(3项)或四价HPV疫苗(11项)。
主要发现
- 14项研究中,2项评估对HPV感染率预防的效果,6项评估生殖器疣,6项评估宫颈细胞学或组织学异常。
- 所有研究均发现三剂次具有显著疫苗效果,11项研究发现两剂次在不同间隔下具有显著效果,6项研究发现一剂次具有显著效果。
- 多数研究显示效果与剂次数之间存在关系(不总是统计学显著),HPV相关结局的下降幅度在三剂次时最大,其次为两剂次和一剂次。
- 少数研究对三剂次与较少剂次进行了正式比较。
- 4项研究检查了缓冲期,其中3项发现缓冲期较长时效果较高且不同剂次间差异较小。
临床怎么用
- 原文未据此给出推荐。
局限性
- 许多研究发现三剂次、两剂次和一剂次受种者之间存在差异,提示接种前HPV暴露或危险行为可能不同。
- 已通过调整或分层分析控制潜在混杂。
- 多种偏倚影响估计值,多数偏倚使两剂次和一剂次的结果偏向不显示效果。
- 未来需要在性活动前接种人群中开展效果研究,并采用减少潜在偏倚来源的方法,以帮助指导疫苗接种政策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV) vaccines were first licensed as a three-dose series; a two-dose series is now recommended in some age groups and there is interest in possible one-dose vaccination. METHODS: We conducted a systematic literature review of HPV vaccine effectiveness by number of doses, including assessment of biases and impact of varying buffer periods (time between vaccination and outcome counting). RESULTS: Of 3787 articles identified, 26 full articles were assessed and 14 included in our review. All studies were conducted within the context of recommended three-dose schedules of bivalent (3) or quadrivalent HPV vaccine (11). Two evaluated effectiveness for prevention of HPV prevalence, six anogenital warts, and six abnormal cervical cytology or histology. Many studies found differences between three-, two- and one-dose vaccine recipients, indicating possible differences in HPV exposure prior to vaccination or in risk behavior. Adjusted or stratified analyses were conducted to control for potential confounding. All studies found significant vaccine effectiveness with three doses, 11 with two doses at various intervals, and six with one dose. Most studies showed a relationship (not always statistically significant) between effectiveness and number of doses, with greater decreases in HPV-related outcomes with three, followed by two and one dose(s). Few studies conducted formal comparisons of three vs fewer doses. Three of four studies that examined buffer periods found higher effectiveness and a smaller difference by number of doses with longer periods. CONCLUSION: Most post-licensure studies report highest effectiveness with three doses; some found no statistically significant difference between two and three doses. Additionally, almost half found some effectiveness with one dose. Several biases impact estimates, with most biasing two- and one-dose results away from showing effectiveness. Future effectiveness studies, examining persons vaccinated prior to sexual activity and using methods to reduce potential sources of bias, can help inform vaccination policy.
引用
- Markowitz LE, Drolet M, Perez N, et al. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine. 2018. PMID: 29802000. doi:10.1016/j.vaccine.2018.01.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。